ArticleJournal of cancer research and clinical oncology2011
Osteosarcoma: improvement in survival limited to high-grade patients only.
Article in Journal of cancer research and clinical oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- Predicting resistance to neoadjuvant chemotherapy in osteosarcoma using machine learning with clinical data and T2-weighted MRI radiomics.European radiology experimental · 2026Article
- Review
- Development and validation of a predictive score for chemoresistance in high-grade osteosarcoma at baseline.Frontiers in medicine · 2025Article
- Tumor-derived exosomal linc00881 induces lung fibroblast activation and promotes osteosarcoma lung migration.Cancer cell international · 2023Article
- Construction and validation of a predictive nomogram for ferroptosis-related genes in osteosarcoma.Journal of cancer research and clinical oncology · 2023Article
- Establishment and validation of a competitive risk model for predicting cancer-specific survival in patients with osteosarcoma: a population-based study.Journal of cancer research and clinical oncology · 2023Article
- Survival benefits and challenges of adjuvant chemotherapy for high-grade osteosarcoma: a population-based study.Journal of orthopaedic surgery and research · 2023Article
- Descriptive Epidemiology and Survival Rate of Osteosarcoma: The First National Population-Based Study in the Middle East (2008-2014).The archives of bone and joint surgery · 2023Article
- Bone mesenchymal stem cell-derived extracellular vesicles containing NORAD promote osteosarcoma by miR-30c-5p.Laboratory investigation; a journal of technical methods and pathology · 2022Article
- α-Linolenic Acid Suppresses Proliferation and Invasion in Osteosarcoma Cells via Inhibiting Fatty Acid Synthase.Molecules (Basel, Switzerland) · 2022Article
- Naringenin Induces ROS-Mediated ER Stress, Autophagy, and Apoptosis in Human Osteosarcoma Cell Lines.Molecules (Basel, Switzerland) · 2022Article
- Hypoxia-immune-related microenvironment prognostic signature for osteosarcoma.Frontiers in cell and developmental biology · 2022Article
- Establishment of a Survival Risk Prediction Model for Adolescent and Adult Osteosarcoma Patients.BioMed research international · 2022Article
- Interpretable clinical visualization model for prediction of prognosis in osteosarcoma: a large cohort data study.Frontiers in oncology · 2022Article
- Prognostic factors, disparity, and equity variables impacting prognosis in bone sarcomas of the hand: SEER database review.Journal of surgical oncology · 2021Article
- Article
- Delay in diagnosis of primary osteosarcoma of bone in children: Have we improved in the last 15 years and what is the impact of delay on diagnosis?Journal of bone oncology · 2021Article
- Article
- Exosomes in osteosarcoma research and preclinical practice.American journal of translational research · 2021Review
- Identification and Development of a Novel 4-Gene Immune-Related Signature to Predict Osteosarcoma Prognosis.Frontiers in molecular biosciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe sought to identify the significant prognostic parameters of patients with osteosarcoma over the past three decades using a population-based registry.
methodsA total of 3765 patients with osteosarcoma were identified in the SEER database. Information regarding patient demographics, clinical and treatment characteristics, cause of death and survival were extracted. Kaplan-Meier, Log-Rank, and Cox regression were used for analysis.
resultsOn multivariate analysis only age group '<25 years', 'local' stage and 'low' grade, 'appendicular skeleton' and employment of 'surgical resection' showed a disease-specific survival benefit with a P value < 0.001. The long-term survival improved in the interval from 1973 to 1985 from approximately 55 to 65% but subsequent improvement has been limited only to patients with high-grade disease.
conclusionWhen comparing survival rates by decade of diagnosis, it appears that improvement in survival since 1985 is limited to patients with high-grade disease only. LEVEL OF EVIDENCE: The level of evidence for this article is 2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.